Table 1

Univariate analysis for GADA, IA-2A, or GADA and/or IA-2A subjects*

GADAIA-2AAby+
CovariateN% PosOR95% CI% PosOR95% CI% PosOR95% CI
Onset age (years)
 2–71,73935.7143.1160.31
 8–131,76747.61.641.42–1.8853.11.501.31–1.7271.61.671.44–1.92
 ≥141,51458.92.572.21–3.0040.60.900.78–1.0469.41.501.28–1.74
Duration (years)
 0–51,84258.6160.4180.61
 6–131,54144.80.570.50–0.6647.20.580.51–0.6768.30.520.44–0.61
 ≥141,63735.60.390.34–0.4528.30.260.22–0.3050.60.250.21–0.29
HLA
 X/X37436.6130.2150.01
 DR3/X62749.61.701.27–2.2726.00.810.60–1.1057.31.34§1.01–1.78
 DR3/DR337457.02.291.66–3.1622.70.68§0.47–0.9865.21.881.36–2.59
 DR3/DR41,84747.91.59§1.23–2.0549.12.231.72–2.8970.22.351.83–3.02
 DR4/X1,27841.81.240.96–1.6156.73.022.31–3.9569.02.231.72–2.89
 DR4/DR452052.51.911.41–2.5959.83.442.52–4.6876.33.232.37–4.40
  • *Individual univariate analyses; dependent variables are GADA, IA-2A, or Aby+, and independent variables (covariate) are either age of onset, duration of disease, or HLA type. Aby+ indicates those who are GADA- and/or IA-2A–positive.

  • % Pos, percentage of antibody-positive subjects; X ≠ DR3 or DR4.

  • P < 0.0001;

  • P < 0.001;

  • §P < 0.05.